Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25822673 | 0.76 | HSPA5 (0.40) | PDPK1LMNAHTT | |
| SCHEMBL29260807 | 0.76 | ALDH1A1 (0.41) | ALDH1A1PARP1MAPTCSNK2A1HTT | |
| SCHEMBL29260806 | 0.76 | ALDH1A1 (0.41) | ALDH1A1PARP1MAPTCSNK2A1HTT | |
| SCHEMBL20471835 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PARP1MAPTCSNK2A1RXFP1 | |
| SCHEMBL23227827 | 0.72 | MAPT (0.47) | ALDH1A1PARP1MAPTCSNK2A1RXFP1 | |
| SCHEMBL5356864 | 0.72 | MAPT (0.44) | ALDH1A1PDPK1PARP1MAPTCSNK2A1 | |
| SCHEMBL15828639 | 0.71 | MAPT (0.36) | ALDH1A1PDPK1PARP1MAPTCSNK2A1 | |
| SCHEMBL17030761 | 0.71 | NOS1 (0.42) | MAPT | |
| SCHEMBL21982936 | 0.71 | — | — | |
| SCHEMBL24104378 | 0.70 | KDM4A (0.33) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647703-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647703-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, G3BP1 | ALDH1A1 3935/4885PDPK1 1248/4885PARP1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.